RETN and chronic kidney disease: In the final GLM models, we found that the addition of PAI-1 to CV risk increases the explained variation of resistin from 5.3% to 14.9% in the CKD group and from 12.1% to 45.7% in individuals with eGFR ≥ 60 mL/min/1.73 m2.